They found that 5.2% of women with pure carcinoma in situ (CIS) had BRCA1/2 mutations (2.3% if women with a family history of breast cancer were excluded) and like Claus et al. that BRCA2 mutations were more common than BRCA1 [13]. The gene discussed is BRCA2; the disease is breast cancer.